Literature DB >> 22778070

Suppository formulations as a potential treatment for nephropathic cystinosis.

Barbara Buchan1, Graeme Kay, Kerr H Matthews, Donald Cairns.   

Abstract

Nephropathic cystinosis is a rare autosomal recessive disease characterised by raised lysosomal levels of cystine in the cells of all the organs. It is treated by the 6-h oral administration of the aminothiol, cysteamine, which has an offensive taste and smell. In an attempt to reduce this frequency and improve the treatment, cysteamine-containing polyethylene glycol suppositories were prepared and evaluated for dissolution and stability. The results demonstrated that cysteamine release was complete after 30 min, and that there was a uniform drug distribution within the formulations. Twelve-month stability tests highlighted a potential incompatibility among some excipients, although stability was demonstrated for the cysteamine suppositories up to 6 months. These suppositories may provide a useful alternative to the current oral therapy for cystinosis.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22778070     DOI: 10.1002/jps.23246

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Evaluation of NACA and diNACA in human cystinosis fibroblast cell cultures as potential treatments for cystinosis.

Authors:  Emma Hector; Donald Cairns; G Michael Wall
Journal:  Orphanet J Rare Dis       Date:  2022-06-16       Impact factor: 4.303

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.